PMID- 36313675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Peripheral absolute eosinophil count identifies the risk of serious 
      immune-related adverse events in non-small cell lung cancer.
PG  - 1004663
LID - 10.3389/fonc.2022.1004663 [doi]
LID - 1004663
AB  - BACKGROUND: Immune-related adverse events (irAEs) have drawn a lot of attention 
      lately as a result of the predominance of immunotherapy in advanced non-small 
      cell lung cancer (NSCLC). However, the clinical evidence for irAEs in real life 
      is limited. In this paper, the occurrence of irAEs in Chinese NSCLC patients was 
      examined, and possible risk factors for the emergence of severe irAEs were 
      discovered. METHODS: Our retrospective investigation assessed the occurrence of 
      adverse events (AEs) and prognosis of 213 patients who received immunotherapy for 
      NSCLC. Using univariate and multivariate logistic regression models, the 
      association between clinicopathological traits and the incidence of severe irAEs 
      was investigated. To assess the prognostic impact of irAEs, survival data was 
      analyzed. RESULTS: Among the 213 NSCLC patients, 122 (57.3%) had irAEs of any 
      grade, and 38 (17.8%) had high-grade (grade 3-5) AEs. Baseline peripheral 
      absolute eosinophil count (AEC) (HR 6.58, 95% CI: 1.5-28.8, P=0.012) was found to 
      be an independent predictor of high-grade irAEs by multivariate analysis. The 
      survival analysis revealed that patients with severe irAEs had worse OS (15.7 vs. 
      20.8 months, 95% CI: 11.6-19.8 vs. 16.0-25.5, P=0.026). CONCLUSION: According to 
      our findings, the peripheral absolute eosinophil count (AEC) is a reliable 
      indicator of severe irAEs in NSCLC. Serious irAEs that occur in patients often 
      reflect poor prognoses. In the future, high-grade irAEs should receive more 
      attention.
CI  - Copyright (c) 2022 Wu, Li, Wu, Yang, Shen and Chen.
FAU - Wu, Yan
AU  - Wu Y
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Li, Dapeng
AU  - Li D
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Wu, Mengyao
AU  - Wu M
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Yang, Ying
AU  - Yang Y
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Shen, Meng
AU  - Shen M
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Chen, Kai
AU  - Chen K
AD  - Department of Oncology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20221013
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9608122
OTO - NOTNLM
OT  - high-grade
OT  - immune-related adverse events
OT  - non-small cell lung cancer
OT  - predictor
OT  - prognosis
OT  - real-world evidence
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/01/01
CRDT- 2022/10/31 05:03
PHST- 2022/07/27 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/31 05:03 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1004663 [doi]
PST - epublish
SO  - Front Oncol. 2022 Oct 13;12:1004663. doi: 10.3389/fonc.2022.1004663. eCollection 
      2022.